Mirtazapine Sandoz

Mirtazapine, the active ingredient in Mirtazapine Sandoz, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adults and helps to improve mood, sleep and appetite.

GNH USA supplies Mirtazapine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression with insomnia: promotes sleep onset and continuity. - Depression with anxiety: alleviates anxiety alongside depressive symptoms.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Orthostatic hypotension.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Seizures. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome). - Hepatic dysfunction. - Suicidal thoughts or behavior, especially early in treatment. - Unusual bleeding or bruising.

When prescribing Mirtazapine, clinicians should consider several safety precautions.

- Hepatic function: assess liver enzymes before initiating therapy. - Weight monitoring: observe for significant weight gain during treatment. - Suicidal ideation: evaluate risk, especially at treatment start. - Elderly patients: use lower doses due to increased sedation risk. - Discontinuation: taper gradually to avoid withdrawal symptoms. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation. - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - Antihypertensive drugs: possible additive blood pressure lowering. - Anticholinergic medications: may exacerbate dry mouth and constipation. - Other antidepressants: monitor for overlapping side‑effect profiles.